Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Geron Corporation

GERNNASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Nov 16, 2026Accepted Nov 16, 2026, 4:30 PM ESTFiling CIK 886744Accession 0001809747-26-000002
Share

Structured filing — 4

form4-11162026_041101.xml

Open full document ↗

Filing details

Report period
2026-11-13
Issuer
GERON CORP
Issuer CIK
0000886744
Trading symbol
GERN

Reporting owner 1

Name
Semerjian Harout
Reporting owner CIK
0001809747
Relationship
Director · Officer
Officer title
President & CEO
Address
C/O GERON CORPORATION, 919 EAST HILLSDALE BOULEVARD, SUITE 250, FOSTER CITY, CA, 94404

Non-derivative transactions

Non-derivative transactions · 1 reported row
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnership
Common Stock2026-11-13P · Form 453,500A.95[F1]53,500D
Table key
P · Form 4
Purchase on the market or privately
A
Acquired
D
Direct

Footnotes

F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9516 to $0.95470, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.↩ 1

Signature 1

Signed
Michelle Robertson, Attorney-in-Fact for Harout Semerjian
Date
2026-11-16

Company context

meaningful moments for people living with blood cancer. Because patients cannot wait, we approach our work with urgency, bringing together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care. Our medicine, RYTELO® (imetelstat), is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes (LR-MDS). Geron is a commercial-stage company with offices in Parsippany, New Jersey and Foster City, California. To learn more, visit www.geron.com or follow us on LinkedIn.

Current securities

Historical securities (1)

Recent company filings

  1. 4 filingNov 16, 2026
  2. SCHEDULE 13G - filed by STATE STREET CORP regarding GERON CORPNov 10, 2026
  3. 10-Q filingNov 4, 2026
  4. Results of Operations and Financial ConditionNov 4, 2026
  5. Other EventsOct 28, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.